Adaptimmune Therapeutics plc (NASDAQ:ADAP - Get Free Report) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.10 and traded as high as $1.23. Adaptimmune Therapeutics shares last traded at $1.21, with a volume of 1,053,968 shares changing hands.
Analyst Ratings Changes
ADAP has been the topic of a number of analyst reports. Mizuho lowered their price target on Adaptimmune Therapeutics from $9.00 to $3.00 and set a "buy" rating on the stock in a research report on Friday, May 17th. StockNews.com upgraded shares of Adaptimmune Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 13th. Scotiabank started coverage on Adaptimmune Therapeutics in a research note on Thursday, May 30th. They issued a "sector outperform" rating and a $3.15 price target on the stock. Finally, HC Wainwright restated a "buy" rating and set a $4.00 price objective on shares of Adaptimmune Therapeutics in a research note on Tuesday, August 13th.
Get Our Latest Report on ADAP
Adaptimmune Therapeutics Stock Performance
The company has a market cap of $298.66 million, a P/E ratio of -1.64 and a beta of 2.31. The firm has a 50 day moving average price of $1.11 and a two-hundred day moving average price of $1.21.
Hedge Funds Weigh In On Adaptimmune Therapeutics
A number of institutional investors have recently bought and sold shares of ADAP. Columbia Advisory Partners LLC purchased a new stake in Adaptimmune Therapeutics in the 1st quarter worth about $25,000. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Adaptimmune Therapeutics in the 1st quarter worth $41,000. Twin Focus Capital Partners LLC purchased a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at approximately $44,000. Boulder Hill Capital Management LP purchased a new position in shares of Adaptimmune Therapeutics in the first quarter worth $143,000. Finally, Renaissance Technologies LLC raised its stake in Adaptimmune Therapeutics by 28.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company's stock worth $1,742,000 after acquiring an additional 394,566 shares during the last quarter. 31.37% of the stock is owned by institutional investors.
About Adaptimmune Therapeutics
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Further Reading
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
